Bagchi Ann D, Esposito Dominick, Kim Myoung, Verdier James, Bencio Deo
Mathemadca Policy Research, Inc., Princeton, New Jersey 08540, USA.
Clin Ther. 2007 Aug;29(8):1771-83. doi: 10.1016/j.clinthera.2007.08.015.
Congestive heart failure (CHF) affects 4.8 million adult Americans, particularly those aged >65 years, and has been described as a "new epidemic" due to the high annual incidence of the disease (an estimated 550,000 new cases per year).
The goal of this research was to determine the number of Medicaid beneficiaries with CHF, identify the rate of CHF drug use, estimate adherence rates, examine factors associated with CHF drug use and adherence, and explore policy implications of the research findings.
Methods used included identifying noninstitutionalized beneficiaries with >or=1 inpatient claim or >or=2 ambulatory claims with a CHF diagnosis and claims for CHF drugs using 1998 State Medicaid Research Files and 1999 Medicaid Analytic eXtract data for Arkansas, California, Indiana, and New Jersey. Patient adherence was estimated using the medication possession ratio (MPR) and days of medication persistence. Multivariate regression models were used to identify factors associated with CHF drug use and adherence.
Overall, 84.8% of beneficiaries had claims for at least 1 CHF medication; 15.2% of beneficiaries were not using any CHF medications. Among those with a claim, the mean number of claims per month was 1.4, and 25.8% had >or=4 claims per month. Mean MPR was 71.9% and mean days of medication persistence were 24.8 per month. Persons aged <65 years, men, ethnic minorities, patients with hospital admissions for conditions other than CHF, and beneficiaries with high Chronic Illness and Disability Payment System scores were less likely to have a CHF drug claim and had lower adherence rates.
State Medicaid agencies and Medicare prescription drug plans should consider designing targeted interventions that encourage better adherence among Medicaid beneficiaries with CHF, particularly men, those aged <65 years, ethnic minorities, and patients with poor overall health status.
充血性心力衰竭(CHF)影响着480万成年美国人,尤其是65岁以上的人群,由于该病的年发病率较高(估计每年有55万新病例),它被描述为一种“新的流行病”。
本研究的目的是确定患有CHF的医疗补助受益人的数量,确定CHF药物的使用率,估计依从率,检查与CHF药物使用和依从性相关的因素,并探讨研究结果的政策含义。
使用的方法包括通过1998年州医疗补助研究档案以及阿肯色州、加利福尼亚州、印第安纳州和新泽西州的1999年医疗补助分析提取物数据,识别有≥1次住院索赔或≥2次门诊索赔且诊断为CHF的非机构化受益人以及CHF药物的索赔。使用药物持有率(MPR)和药物持续天数来估计患者的依从性。多元回归模型用于识别与CHF药物使用和依从性相关的因素。
总体而言,84.8%的受益人至少有1次CHF药物索赔;15.2%的受益人未使用任何CHF药物。在有索赔的人群中,每月索赔的平均次数为1.4次,25.8%的人每月有≥4次索赔。平均MPR为71.9%,平均药物持续天数为每月24.8天。年龄<65岁的人、男性、少数族裔、因CHF以外的疾病住院的患者以及慢性疾病和残疾支付系统得分高的受益人更不太可能有CHF药物索赔且依从率较低。
州医疗补助机构和医疗保险处方药计划应考虑设计有针对性的干预措施,以鼓励患有CHF的医疗补助受益人,特别是男性、年龄<65岁的人、少数族裔以及总体健康状况较差的患者更好地依从。